Moderna’s Covid-19/influenza vaccine phase III data highlights potential of mRNA technology for infectious diseases: GlobalData Read more
Moderna’s mRESVIA FDA approval paves way for mRNA vaccines across multiple indications: GlobalData Read more
Moderna, Life Edit Therapeutics collaborate for R&D of novel in vivo gene editing therapies Read more
Moderna’s non-vaccine mRNA therapeutic can generate $278 million in 2028 if approved: GlobalData Read more